%PDF-1.5
%
59 0 obj
<>
endobj
61 0 obj
<>stream
2016-08-08T15:08:56-05:00
QuarkXPress(R) 9.3
2024-03-29T00:55:07-07:00
2024-03-29T00:55:07-07:00
QuarkXPress(R) 9.3
application/pdf
An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial
%%DocumentProcessColors: Black
%%EndComments
uuid:ac09a1b9-1dd1-11b2-0a00-370927fd5800
uuid:ac09a1bd-1dd1-11b2-0a00-6a0000000000
endstream
endobj
19 0 obj
<>]>>
endobj
49 0 obj
<>
endobj
48 0 obj
<>
endobj
56 0 obj
<>
endobj
57 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/TrimBox[0 0 585 783]/Type/Page/u2pMat[1 0 0 -1 0 783]/xb1 0/xb2 585/xt1 0/xt2 585/yb1 0/yb2 783/yt1 0/yt2 783>>
endobj
58 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/TrimBox[0 0 585 783]/Type/Page/u2pMat[1 0 0 -1 0 783]/xb1 0/xb2 585/xt1 0/xt2 585/yb1 0/yb2 783/yt1 0/yt2 783>>
endobj
68 0 obj
[73 0 R]
endobj
69 0 obj
<>stream
HW]o:}pۤoaE!ǟ7(0w7o".7O
5'Yg>egbp4/ռ+/y>\[.7S𬟞bs2ǫ;][Mvv}}TnbQٗe'͋T~l/7V0F\٧ۛ_*Ο'g6Cv6ao~ko`T\H5,ftp~xvOc::`ˤBRH"ؤ/}-/KwQ!&cXgR8ͳqȣ~G@J~KwG;V8~)0En`i!Gv\b<\`MD6|0*.s9僋chyq6_1;֒ e*ЕEK~x-,@
y2ڋeC j
}6En^^2_LMi@4$^l8]Щݜ)Si9IH\=GddA5eDŽmZkZ5F薄Gس
8k0{!d( c.UraC$-61r>ILD
U(Sqa ݘNE>E 3ˇhn^X.i
SNP3d)ZEr$*r}naȩ"OOfvNJL4bGe6MX%SnǺ&{M?%(gw 0FӂP#
l],fK":IP:s@yĄGb